|
SAN DIEGO, June 24, 2004 - La Jolla Pharmaceutical Company
(Nasdaq: LJPC)
today announced that two articles were published in the journal
Lupus (Vol. 13, Issue 5)
reviewing the Company’s drug candidates Riquent® (abetimus
sodium, formerly LJP
394) for the treatment of lupus renal disease and LJP 1082 for the
treatment of
antibody-mediated thrombosis. The articles summarize the large body
of previously
announced data collected from several clinical studies evaluating
Riquent as well as the
Company’s tolerance technology.
Two leading lupus clinicians, Daniel Wallace, M.D., Clinical Professor
of Medicine,
Department of Medicine, Division of Rheumatology, Cedars-Sinai/UCLA
School of
Medicine, and James Tumlin, M.D., Associate Professor of Medicine,
Renal Division,
Emory University Medical School, published a paper (page 323-327)
entitled: “LJP 394
(Abetimus Sodium, Riquent) in the Management of Systemic Lupus Erythematosus.”
The paper summarizes the clinical development of Riquent and focuses
on results from
the Phase 2/3 and Phase 3 clinical trials, in which Drs. Wallace
and Tumlin were clinical
investigators. The data from these trials support the Company’s
New Drug Application
for Riquent currently under FDA review.
In the same issue, Joan Merrill, M.D., Clinical Pharmacology Research
Program,
Oklahoma Medical Research Foundation, published an article (page
335-338) entitled:
“LJP 1082: A Toleragen for Hughes Syndrome.” The article
discusses B cell tolerance
and summarizes the clinical rationale for LJP 1082, the Company’s
drug candidate
specifically designed to treat the underlying cause of antibody-mediated
thrombosis.
Dr. Merrill is a leading clinical researcher in antibody-mediated
thrombosis and was a
clinical investigator in a Phase 1/2 clinical trial of LJP 1082,
which was completed in
October 2002.
|
Message
Boards
